Severe Asthma, MepolizumaB and Affect: SAMBA Study
| 대상 질환 | Severe Eosinophilic Asthma, Psychological Distress, Anxiety, Depression |
|---|---|
| 임상 단계 | 단계 해당 없음 |
| 스폰서 | University Hospital Southampton NHS Foundation Trust |
| 상태 | 완료 |
| 참여자 수 | 120 명 |
| 중재(약물) | no study intervention. Patients receive standard clinical care |
| 시작일 | 2021년 9월 9일 |
| 완료일 | 2025년 3월 26일 |
| 결과 공개일 | 2026년 7월 13일 |
요약
This is a real-life pragmatic non-randomised study to explore the impact of mepolizumab on the emotional and affective outcomes of patients with severe eosinophilic asthma and their partners. It will be conducted in two quantitative stages (Phases 1 and 2) with an additional third qualitative component (Phase 3).
Change in Emotional Composition (Using the Geneva Emotions Wheel)
| Patients With Severe Eosinophilic Asthma Phase 2 | 0.9 score |
|---|---|
| Partners of Patients With Severe Eosinophilic Asthma Phase 2 | 0.1 score |
| Patients With Severe Eosinophilic Asthma Phase 2 | 0.7 score |
| Partners of Patients With Severe Eosinophilic Asthma Phase 2 | 0.0 score |
| Patients With Severe Eosinophilic Asthma Phase 2 | 0.0 score |
| Partners of Patients With Severe Eosinophilic Asthma Phase 2 | 0.2 score |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- CBT+ for Depression — University of Wisconsin, Madison
- Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital
- Individualized Functional Connectivity Targeting in aiTBS for Depression — Brigham and Women's Hospital